Provided by Tiger Trade Technology Pte. Ltd.

Viridian Therapeutics, Inc.

28.35
+1.164.27%
Post-market: 28.350.00000.00%18:55 EDT
Volume:1.15M
Turnover:32.62M
Market Cap:2.90B
PE:-8.53
High:28.59
Open:27.24
Low:27.10
Close:27.19
52wk High:34.29
52wk Low:9.90
Shares:102.21M
Float Shares:102.00M
Volume Ratio:0.57
T/O Rate:1.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3245
EPS(LYR):-3.3245
ROE:-49.16%
ROA:-27.67%
PB:4.91
PE(LYR):-8.53

Loading ...

Viridian Therapeutics Inc - Ind Submitted for Vrdn-008; Hv Data Expected in 2H 2026

THOMSON REUTERS
·
Jan 06

Viridian Therapeutics : Expects Its Current Business Plans to Be Funded Through Profitability

THOMSON REUTERS
·
Jan 06

FDA Accepts Viridian Therapeutics' Veligrotug BLA for Priority Review

Reuters
·
Jan 06

Viridian Therapeutics Chief Legal Officer Jennifer Tousignant Reports Disposal of Common Shares

Reuters
·
Jan 03

Exploring US High Growth Tech Stocks In December 2025

Simply Wall St.
·
Dec 25, 2025

Viridian Therapeutics Inc : Needham Raises Target Price to $42 From $34

THOMSON REUTERS
·
Dec 23, 2025

FDA Grants Priority Review to Viridian Therapeutics' Veligrotug for Thyroid Eye Disease

Reuters
·
Dec 22, 2025

Viridian Therapeutics Inc - Pdufa Target Action Date Set for June 30, 2026

THOMSON REUTERS
·
Dec 22, 2025

Viridian Therapeutics Announces Bla Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease

THOMSON REUTERS
·
Dec 22, 2025

Viridian Therapeutics Inc - Plans to Submit Marketing Authorization Application to Ema in Q1 2026

THOMSON REUTERS
·
Dec 22, 2025

FDA Review Of Veli For Thyroid Eye Disease Might Change The Case For Investing In Viridian Therapeutics (VRDN)

Simply Wall St.
·
Dec 21, 2025

Viridian Therapeutics Inc : Wedbush Raises Target Price to $47 From $42

THOMSON REUTERS
·
Dec 10, 2025

Evaluating Viridian Therapeutics (VRDN) After William Blair’s New ‘Outperform’ Rating and Rising Investor Optimism

Simply Wall St.
·
Dec 06, 2025

BRIEF-Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Dec 05, 2025

Viridian Therapeutics Grants Stock Options to New Employees as Inducement Awards

Reuters
·
Dec 05, 2025

Will William Blair’s Outperform Initiation Shift Viridian Therapeutics’ (VRDN) Narrative Among Institutional Investors?

Simply Wall St.
·
Dec 04, 2025

Viridian Therapeutics Inc : William Blair Initiates Coverage With Outperform Rating

THOMSON REUTERS
·
Dec 03, 2025

Exploring 3 High Growth Tech Stocks in the US Market

Simply Wall St.
·
Nov 25, 2025

Truist Financial Initiates a Buy Rating on Viridian Therapeutics (VRDN)

TIPRANKS
·
Nov 24, 2025

H.C. Wainwright Sticks to Their Buy Rating for Viridian Therapeutics (VRDN)

TIPRANKS
·
Nov 10, 2025